Share Price | Lexaria Bioscience Corp. Stock Analysis & Recommendation

Q: How big is Lexaria Bioscience Corp.?

Market Cap: As of Jun 18, Lexaria Bioscience Corp. has a market capitalization of 19.48 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Lexaria Bioscience Corp. reported net sales of 0.51 million and a net profit of -9.40 million.Balance Sheet Snapshot: As of Aug 24, the company's shareholder's funds amounted to 8.04 million, while total assets were reported at 8.87 million.

Q: What does Lexaria Bioscience Corp. do?

Overview: Lexaria Bioscience Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Feb 2025) Most recent Net Profit: -3 Million (Quarterly Results - Feb 2025) Market-cap: USD 19.48 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.91 Return on Equity: -130.81% Price to Book: 2.73Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Lexaria Bioscience Corp. technically bullish or bearish?

As of 25 August 2025, the technical trend for Lexaria Bioscience Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The MACD is mildly bullish on the weekly timeframe but bearish on the monthly. The RSI shows a bullish signal on the monthly but no signal on the weekly. Moving averages indicate a mildly bearish trend on the daily. The stock has outperformed the S&P 500 over the past week and month, returning 14.02% and 45.85% respectively, but has significantly underperformed over longer periods, with a year-to-date return of -41.90% compared to the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

38.63 k

Shareholding (Nov 2025)

FII

3.13%

Held by 12 FIIs

DII

94.39%

Held by 3 DIIs

Promoter

0.00%

How big is Lexaria Bioscience Corp.?

22-Jun-2025

As of Jun 18, Lexaria Bioscience Corp. has a market capitalization of 19.48 million, with net sales of 0.51 million and a net profit of -9.40 million over the last four quarters. The company's shareholder's funds are 8.04 million, and total assets are 8.87 million as of Aug 24.

View full answer

What does Lexaria Bioscience Corp. do?

22-Jun-2025

Lexaria Bioscience Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $3 million as of February 2025, with a market cap of $19.48 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -130.81%.

View full answer

Is Lexaria Bioscience Corp. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Lexaria Bioscience Corp. is in a mildly bearish trend, with mixed technical indicators showing short-term outperformance against the S&P 500 but significant underperformance year-to-date.

View full answer

Compare Lexaria Bioscience Corp. with Similar Stocks

Sunshine Biopharma, Inc.Comera Life Sciences Holdings, Inc.Blue Water Biotech, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 18 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.89

Return on Equity

-214.71%

Price to Book

3.58

Revenue and Profits:

Net Sales:

(Quarterly Results - Nov 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

17.74%

6 Months

-44.27%

1 Year

-58.76%

2 Years

-78.96%

3 Years

-71.48%

4 Years

-76.75%

5 Years

-86.43%

Lexaria Bioscience Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.66%

EBIT Growth (5y)

-190.44%

EBIT to Interest (avg)

-6.91

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.83

Sales to Capital Employed (avg)

0.09

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

17.63%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.58

EV to EBIT

-1.25

EV to EBITDA

-1.26

EV to Capital Employed

13.22

EV to Sales

13.22

PEG Ratio

Dividend Yield

ROCE (Latest)

-1054.98%

ROE (Latest)

-214.71%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Nov 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (2.48%)

Foreign Institutions

Held by 12 Foreign Institutions (3.13%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Nov'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Nov 2025 is -100.00% vs 0.00% in Aug 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Nov 2025 is 40.74% vs 28.95% in Aug 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Nov'25",
        "Aug'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.50",
          "val2": "-2.50",
          "chgp": "40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.60",
          "val2": "-2.70",
          "chgp": "40.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-14,222.80%",
          "chgp": "1,422.28%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Aug'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Aug 2025 is 40.00% vs 150.00% in Aug 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Aug 2025 is -105.17% vs 13.43% in Aug 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Aug'25",
        "Aug'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.70",
          "val2": "0.50",
          "chgp": "40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.50",
          "val2": "-5.60",
          "chgp": "-105.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.30",
          "val2": "-0.10",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.90",
          "val2": "-5.80",
          "chgp": "-105.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-16,479.70%",
          "val2": "-12,267.00%",
          "chgp": "-421.27%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Nov'25 - QoQ

Nov'25

Aug'25

Change(%)

Net Sales

0.00

0.20

-100.00%

Operating Profit (PBDIT) excl Other Income

-1.50

-2.50

40.00%

Interest

0.00

Exceptional Items

-0.00

-0.20

100.00%

Consolidate Net Profit

-1.60

-2.70

40.74%

Operating Profit Margin (Excl OI)

0.00%

-14,222.80%

1,422.28%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Nov 2025 is -100.00% vs 0.00% in Aug 2025

Consolidated Net Profit

QoQ Growth in quarter ended Nov 2025 is 40.74% vs 28.95% in Aug 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Aug'25

Aug'25

Aug'24

Change(%)

Net Sales

0.70

0.50

40.00%

Operating Profit (PBDIT) excl Other Income

-11.50

-5.60

-105.36%

Interest

0.00

Exceptional Items

-0.30

-0.10

-200.00%

Consolidate Net Profit

-11.90

-5.80

-105.17%

Operating Profit Margin (Excl OI)

-16,479.70%

-12,267.00%

-421.27%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Aug 2025 is 40.00% vs 150.00% in Aug 2024

Consolidated Net Profit

YoY Growth in year ended Aug 2025 is -105.17% vs 13.43% in Aug 2024

All Annual Results

Company CV

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available